Roivant Sciences Ltd.
ROIVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRoivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. The $21.49B market capitalization puts ROIV squarely in large-cap range for its industry. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Market Cap
$21.49B
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
-19.16
EPS (TTM)
$-0.54
EPS (Fwd)
$-1.56
ROE
-7.6%
ROA
-14.3%
Cash
$4.29B
Total Debt
$107.4M
Free CF
-$1.09B
52W Change
171.9%
Annual Financials
Cash vs Debt
Roivant Sciences Ltd. holds $4.29B in cash against $107.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$1.09B. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -7.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $31.5M (2023) to $8.3M (2026), a 74% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Roivant Sciences Ltd.'s trajectory.